Abstract：Objective To evaluate the clinical efficacy of prophylactic cranial irradiation (PCI) in the treatment of surgically resected small cell lung cancer (SCLC). Methods Clinical data of SCLC patients undergoing radical resection surgery in Zhejiang Cancer Hospital from 2003 to 2015 were retrospectively analyzed. According to the treatment modality,all patients were allocated into the PCI and non-PCI groups. A total of 52 patients were finally included,including 19 patients in the PCI group (5 cases of stage Ⅰ,5 stage Ⅱ and 9 stage Ⅲ) and 33 in the non-PCI group (12 cases of stage Ⅰ,5 stage Ⅱ and 16 stage Ⅲ).Kaplan-Meier method was utilized for survival analysis. Cox proportional hazards model was adopted to analyze clinical prognosis. Results The median survival time was 32.9 months in the PCI group,and 20.4 months in the non-PCI group. The 2-year overall survival rate was 72% in the PCI group,significantly higher than 38% in the non-PCI group (P=0.023).The median brain metastasis-free survival (BMFS) was 32.5 months in the PCI group,and 17.1 months in the non-PCI group. In the PCI group,the 2-year BMFS rate was 89%,significantly better than 53% in the non-PCI group (P=0.026).Subgroup analysis demonstrated that PCI could confer survival benefit to patients with p-stage Ⅲ(P=0.031) rather than p-stage Ⅰ(P=0.924) and Ⅱ(P=0.094) counterparts. Multivariate analysis revealed that PCI (HR=0.330,P=0.041) was an independent prognostic factor of the overall survival. Conclusions PCI can reduce thr risk of brain metastasis rate and improve the overall survival of patients with surgically resected SCLC.
Chen Mengyuan,Hu Xiao,Xu Yujin et al. Clinical efficacy of prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 895-899.
[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].Clin Oncol,2006,24(28):4539-4544.DOI:10.1200/JCO.2005.04.4859. [2] Arriagada R,Le Chevalier T,Borie F,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J].J Natl Cancer Inst,1995,87(3):183-190. [3] Aupérin A,Arriagada R,Pignon JP,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J].N Engl J Med,1999,341(7):476-484.DOI:10.1056/NEJM199908123410703. [4] Bloom BC,Augustyn A,Sepesi B,et al. Prophylactic cranial irradiation following surgical resection of early-stage small-cell lung cancer:a review of the literature[J].Front Oncol,2017,7(9):228.DOI:10.3389/fonc.2017.00228. [5] Vinés EF, Le Péchoux C, Arriagada R. Prophylactic cranial irradiation in small cell lung cancer [ J]. Semin Oncol, 2003, 30(1):38-46. DOI: 10.1053/sonc.2003.50013b [6] Auperin A,Arriagada R,Pignon JP,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group[J].N Engl J Med.1999,341(7):476-484.DOI:10.1056/NEJM199908123410703. [7] Nakamura H,Kato Y,Kato H,et al. Outcome of surgery for small-cell lung cancer-response to induction chemotherapy predicts survival[J].Thorac Cardiovasc Surg,2004,52(4):206-210.DOI:10.1055/s-2004-821075. [8] Tsuchiya R,Suzuki K,Ichinose Y,et al. Phase Ⅱ trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-ⅢA small-cell lung cancer:the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)[J].J Thorac Cardiovasc Surg,2005,129(5):977-983.DOI:10.1016/j.jtcvs.2004.05.030. [9] Gong L,Wang QI,Zhao L,et al. Factors Affecting the risk of brain metastasis in small cell lung cancer with surgery:is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease?[J].Int J Radiation Oncol Biol Phys,2013,85(1):196-200.DOI:10.1016/j.ijrobp.2012.03.038. [10] Hui Z,Hongbo G,Fang S,et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer,but not for stage Ⅰ disease[J].Lung Cancer,2014,86(3):334-338.DOI:10.1016/j.lungcan.2014.09.019. [11] Xu J,Yang H,Fu X,et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J].J Thorac Oncol,2016,26(16):1556-1564.DOI:10.1016/j.jtho.2016.09.133. [12] Bischof M,Debus J,Herarth K,et al. Surgery and chemotherapy for small-cell lung cancer in stages Ⅰ-Ⅱ with or without radiotherapy[J].Strahlenther Onkol,2007,183(12):679-684.DOI:10.1007/s00066-007-1740-z. [13] Chi-Fu JY,Derek Y,Paul J,et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer[J].J Clin Oncol,2016,34(10):1057-1064.DOI:10.1200/JCO.2015.63.8171.
2018, Vol. 27 
